Live Breaking News & Updates on Academic Physiatrists Annual Meeting

Stay updated with breaking news from Academic physiatrists annual meeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

- Provides Revance entry into the $2.5 billion U.S. therapeutic neuromodulator market.1

- Approval expands the DAXXIFY® label to include efficacy data over the 52-week ASPEN repeat dose clinical.
-Today at 08:04 am- MarketScreener ....

United States , Markj Foley , Peter Mcallister , Association Of Academic Physiatrists Annual Meeting , Peptide Exchange Technology , Revance Therapeutics Inc , American Academy Of Physical Medicine , Securities Exchange , Dystonia Medical Research Foundation , Drug Administration , Exchange Commission , England Institute For Neurology , Hint Inc , Viatris Inc , Revance Therapeutics , Chief Executive Officer Mark , New England Institute , Label Study , Boxed Warning , Distant Spread , Specific Populations , Prescribing Information , Relational Commerce , Shanghai Fosun Pharmaceutical , Resilient Hyaluronic Acid , Private Securities Litigation Reform Act ,